Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | August 17, 2026 | August 20, 2026 |
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director | June 10, 2026 | June 12, 2026 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | Director | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date August 17, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,625 |
Ending reported balance
After 2026-08-17 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-17 · Exercise / conversion · Acquired 15,000 · Balance 255,315 Row 2 · 2026-08-17 · Sale · Disposed 15,000 · Balance 240,315 F1: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.27, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-08-17 · Sale · Disposed 40,000 · Balance 200,315 F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.17, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 4 · 2026-08-17 · Sale · Disposed 69,690 · Balance 130,625 F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 to $25.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 | Direct | 0 |
Reported balance
After 2026-08-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-17 · Exercise / conversion · Disposed 15,000 · Balance 0 F4: The option was fully vested and exercisable and would have expired on October 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.27, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.17, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 to $25.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The option was fully vested and exercisable and would have expired on October 18, 2026.
Fortrea Holdings Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 12,852 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 12,852 · Balance 12,852 F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F2: Represents an RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service. F3: This number reflects the aggregate number of RSUs held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock").
F2: Represents an RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service.
F3: This number reflects the aggregate number of RSUs held by the reporting person.
LABCORP HOLDINGS INC.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,784 |
Reported balance
After 2026-02-11 transaction · row 1
1 source rowRow 1 · 2026-02-11 · Exercise / conversion · Acquired 897 · Balance 13,784 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 773 |
Reported balance
After 2026-02-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-11 · Exercise / conversion · Disposed 897 · Balance 773 F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2: The Restricted Stock Units vested fully on February 11, 2026. F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F2: The Restricted Stock Units vested fully on February 11, 2026.
F3: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 20, 2026 00:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001237566-26-000003 · primary_doc.xml · derivative · entry 5 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The option was fully vested and exercisable and would have expired on October 18, 2026. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 69,690 | $25.16 | $1,753,400.40 |
DisclosureSEC source: 0001237566-26-000003 · primary_doc.xml · nonDerivative · entry 4 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,625 F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 to $25.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 40,000 | $25.10 | $1,004,000.00 |
DisclosureSEC source: 0001237566-26-000003 · primary_doc.xml · nonDerivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,315 F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.17, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 15,000 | $25.23 | $378,450.00 |
DisclosureSEC source: 0001237566-26-000003 · primary_doc.xml · nonDerivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,315 F1 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.27, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| August 17, 2026 Filed Aug 20, 2026 00:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.32 | $94,800.00 |
DisclosureSEC source: 0001237566-26-000003 · primary_doc.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:13 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 12,852 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000083 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,852 Underlying: Common Stock · 12,852 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). F2 · derivative.exercise_date: Represents an RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service. F2 · derivative.expiration_date: Represents an RSU award that vests in its entirety twelve months after June 10, 2026, subject to the Reporting Person's continued service. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:34 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 148,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000057 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 148,536 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F3 · derivative.exercise_date: Represents an RSU award that vested in its entirety on May 14, 2026. F3 · derivative.expiration_date: Represents an RSU award that vested in its entirety on May 14, 2026. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:34 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 148,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001965040-26-000057 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") common stock ("Common Stock"). This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:59 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001237566-26-000001 · primary_doc.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,315 Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 17:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000075 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773 Underlying: Common Stock · 897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2026. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 17:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000075 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 16:05 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000048 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,670 Underlying: Common Stock · 773 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 10, 2027. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 10, 2027. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 00:21 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | PurchaseCommon Stock | 32,500 | $6.26 | $203,450.00 |
DisclosureSEC source: 0001127602-25-020326 · form4.xml · nonDerivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,132 F1 · security: The purchases reported on this Form 4 represent shares of Common Stock purchased by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $6.15 to $6.39. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 00:21 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | PurchaseCommon Stock | 30,000 | $6.79 | $203,700.00 |
DisclosureSEC source: 0001127602-25-020326 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,632 F1 · security: The purchases reported on this Form 4 represent shares of Common Stock purchased by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $6.69 to $6.90. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:42 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 148,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014729 · form4.xml · derivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,536 Underlying: Common Stock · 148,536 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of Fortrea Holdings Inc. Common Stock. F5 · derivative.exercise_date: Represents an RSU award that vests in its entirety twelve months after May 14, 2025, subject to the Reporting Person's continued service. F5 · derivative.expiration_date: Represents an RSU award that vests in its entirety twelve months after May 14, 2025, subject to the Reporting Person's continued service. F6 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:42 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014729 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F3 · derivative.exercise_date: Represents an RSU award that vested in its entirety on May 14, 2025. F3 · derivative.expiration_date: Represents an RSU award that vested in its entirety on May 14, 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:42 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014729 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:47 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001062993-25-005299 · form4.xml · derivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was fully vested and exercisable. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:47 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $7.05 | $70,500.00 |
DisclosureSEC source: 0001062993-25-005299 · form4.xml · nonDerivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,690 F1 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.03 to 7.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 23:47 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 50,000 | $4.07 | $203,500.00 |
DisclosureSEC source: 0001062993-25-005299 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,726 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001062993-25-004805 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,726 Underlying: Common Stock · 23,726 shares Expires 2035-03-04 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:16 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 15,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004805 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,690 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 13:24 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004518 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 897 Underlying: Common Stock · 897 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2026. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2026. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 13:54 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003708 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. ("LHI") Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 6, 2025. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 13:54 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-003708 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. ("LHI") Common Stock. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 21:23 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020751 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,282 Underlying: Common Stock · 6,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F3 · derivative.exercise_date: The RSUs vested on July 18, 2024. F3 · derivative.expiration_date: The RSUs vested on July 18, 2024. F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 21:23 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | Exercise / conversionCommon Stock | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-020751 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · balance_after: This number reflects the aggregate amount of Common Stock held by the reporting person. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:34 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 7,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015689 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,636 Underlying: Common Stock · 7,282 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: Represents a RSU award that vests in its entirety twelve months after May 14, 2024, subject to the Reporting Person's continued service as a director. F3 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 21:55 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001062993-24-006350 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was fully vested as of January 1, 2015. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 21:55 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $0.84 | $12,600.00 |
DisclosureSEC source: 0001062993-24-006350 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 48,044 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001062993-24-005773 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,044 Underlying: Common Stock · 48,044 shares Expires 2034-03-04 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2024, subject to continued service as a director through such vesting dates. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:45 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 31,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005773 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,296 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003890 · form4.xml · derivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 944 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vested fully on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vested fully on February 7, 2024. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 17:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003890 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 17:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003890 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,891 Underlying: Common Stock · 944 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 6, 2025. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 6, 2025. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 98 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001062993-23-022626 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2023-12-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested with respect to 1/4 of the Shares under the grant on the year anniversary of December 23, 2013 and with respect to 1/48 of the Shares under the grant monthly thereafter. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 21:21 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 100,000 | $0.84 | $84,000.00 |
DisclosureSEC source: 0001062993-23-022626 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2023 Filed Aug 24, 2023 01:12 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | PurchaseCommon Stock | 11,000 | $25.30 | $278,256.00 |
DisclosureSEC source: 0001127602-23-023158 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,996 F1 · price: This transaction was executed in multiple trades at prices ranging from $25.15 to $25.38. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 18, 2023 Filed Jul 19, 2023 21:12 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | GrantRestricted Stock Unit · Derivative | 6,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-021039 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,354 Underlying: Common Stock · 6,354 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Fortrea Holdings Inc. Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. F2 · derivative.expiration_date: The RSUs vest in full on July 18, 2024, subject to the Reporting Person's continued service as a director. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 23,329 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006335 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,329 Underlying: Common Stock · 23,329 shares Expires 2033-03-06 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year from March 4, 2023, subject to continued service as a director through such vesting dates. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006335 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,968 Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005109 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005109 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 17:26 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 849 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004129 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,591 Underlying: Common Stock · 849 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 7, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 7, 2024. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 16, 2022 Filed Feb 19, 2022 01:46 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | PurchaseCommon Stock | 600 | $264.57 | $158,742.00 |
DisclosureSEC source: 0001127602-22-005820 · form4.xml · nonDerivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,254 F3 · price: The price of $264.57 per share represents a weighted average of purchase prices ranging from $264.49 to $264.97 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 16, 2022 Filed Feb 19, 2022 01:46 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | PurchaseCommon Stock | 1,600 | $263.98 | $422,368.00 |
DisclosureSEC source: 0001127602-22-005820 · form4.xml · nonDerivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,654 F2 · price: The price of $263.98 per share represents a weighted average of purchase prices ranging from $263.38 to $264.35 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 16, 2022 Filed Feb 19, 2022 01:46 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | PurchaseCommon Stock | 1,300 | $262.85 | $341,705.00 |
DisclosureSEC source: 0001127602-22-005820 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,054 F1 · price: The price of $262.85 per share represents a weighted average of purchase prices ranging from $262.18 to $263.16 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:31 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004954 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 771 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003412 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 2, 2022. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003412 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.